Tag Archives: Victoria M. Villaflor MD

AstraZeneca’s Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option

(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release